Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (181-190 of 322) with videos related to

Pageof 33
Sort By:
Leukemia Research|June 11, 2020
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I studyAaron D Goldberg, Ehab Atallah, David Rizzieri, et al.
Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.
Ejhaem|June 16, 2025
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax TherapyRafael Madero-Marroquin, Joseph Cannova, Emily Dworkin, et al.
Cancer|November 24, 2020
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemiaWendy Stock, Giovanni Martinelli, Matthias Stelljes, et al.
American Journal of Hematology|July 31, 2018
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimensStuart E Siegel, Anjali Advani, Nita Seibel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 26, 2016
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity ConditioningStephanie B Tsai, Hongtao Liu, Tsiporah Shore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSMichael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Leukemia & Lymphoma|October 29, 2013
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotypeXavier Poiré, Barry K Moser, Robert E Gallagher, et al.
Blood|October 7, 2011
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissionsHongtao Liu, Elizabeth S Rich, Lucy Godley, et al.
The Lancet. Oncology|October 19, 2012
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 studyHagop Kantarjian, Stefan Faderl, Guillermo Garcia-Manero, et al.
Pageof 33

Showing results (181-190 of 322) with videos related to

Sort By:
Pageof 33
Leukemia Research|June 11, 2020
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I studyAaron D Goldberg, Ehab Atallah, David Rizzieri, et al.
Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.
Ejhaem|June 16, 2025
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax TherapyRafael Madero-Marroquin, Joseph Cannova, Emily Dworkin, et al.
Cancer|November 24, 2020
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemiaWendy Stock, Giovanni Martinelli, Matthias Stelljes, et al.
American Journal of Hematology|July 31, 2018
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimensStuart E Siegel, Anjali Advani, Nita Seibel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 26, 2016
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity ConditioningStephanie B Tsai, Hongtao Liu, Tsiporah Shore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSMichael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Leukemia & Lymphoma|October 29, 2013
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotypeXavier Poiré, Barry K Moser, Robert E Gallagher, et al.
Blood|October 7, 2011
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissionsHongtao Liu, Elizabeth S Rich, Lucy Godley, et al.
The Lancet. Oncology|October 19, 2012
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 studyHagop Kantarjian, Stefan Faderl, Guillermo Garcia-Manero, et al.
Pageof 33